Methods and formulations for use in inhibiting conception and in treating benign gynecological disorders

A composition comprising:

• a slow-release formulation of a gonadotropin hormone releasing hormone composition which maintains serum level of said gonadotropin hormone releasing hormone composition in a female mammal at a level effective to suppress ovarian estrogen and progesterone production over a period of time, said GnRH composition being administered so as to provide between about 0.0001 and about 10 mg/kg of body weight per day;
• a slow-release formulation of an estrogenic composition which maintains serum level of said estrogenic composition over said period of time at a level effective to prevent symptoms of estrogen deficiency, said level being equivalent to a serum level of estradiol of between about 25 and about 140 pg/ml;
• and
• a slow-release formulation of a progestogen which maintains serum level of said progestogen over said period of time at a level effective to decrease endometrial cell proliferation, said level being equivalent to a serum level of progesterone of between about 0.5 and about 4 ng/ml.

A method for preventing conception in a mammal or for treating benign gynecological disorders, comprising:

• administering a gonadotropin hormone releasing hormone composition for a first period of time in an amount effective to maintain serum level of said gonadotropin hormone releasing hormone composition at a level effective to suppress ovarian estrogen and progesterone production, said GnRH composition being administered so as to provide between about 0.0001 and about 10 mg/kg of body weight per day;
• simultaneously administering an estrogenic composition in an amount effective to maintain serum level of said estrogenic composition over said first period of time at a level effective to prevent symptoms of estrogen deficiency, said level being equivalent to a serum level of estradiol of between about 25 and about 140 pg/ml;
• and
• administering a progestogen for a second, shorter period of time in an amount effective to maintain serum level of said progestogen at a first level effective to induce a secretory endometrium for at least 5 to about 20 days and at a second lower level effective to decrease endometrial cell proliferation for a remainder, if any, of said second period of time, said second period of time being substantially shorter than and running simultaneously with a portion of said first period of time, said first level being equivalent to a serum level of progesterone of between about 5 and about 20 ng/ml and said second level being equivalent to a serum level of progesterone of between about 0.5 and about 4 ng/ml.

A method for preventing conception in a mammal or for treating benign gynecological disorders, comprising:

• administering a gonadotropin hormone releasing hormone composition for a period of time in an amount effective to maintain serum level of said gonadotropin hormone releasing hormone composition at a level effective to suppress ovarian estrogen and progesterone production, said GnRH composition being administered so as to provide between about 0.0001 and about 10 mg/kg of body weight per day;
• simultaneously administering an estrogenic composition in an amount effective to maintain serum level of said estrogenic composition over said period of time at a level effective to prevent symptoms of estrogen deficiency, said level being equivalent to a serum level of estradiol of between about 25 and about 140 pg/ml;
• and
• simultaneously administering a progestogen in an amount effective to maintain serum level of said progestogen over said period of time at a level effective decrease endometrial cell proliferation, said level being equivalent to a serum level of progesterone of between about 0.5 and about 4 ng/ml.